{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:27:47Z","timestamp":1794605267072,"version":"4.9.1"},"reference-count":259,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1038\/s41584-023-01033-0","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T08:02:49Z","timestamp":1696579369000},"page":"695-712","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Epidemiology of the idiopathic inflammatory myopathies"],"prefix":"10.1038","volume":"19","author":[{"given":"Thomas","family":"Khoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9230-4137","authenticated-orcid":false,"given":"James B.","family":"Lilleker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6338-8482","authenticated-orcid":false,"given":"Bernard Yu-Hor","family":"Thong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Leclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7248-0539","authenticated-orcid":false,"given":"Janine A.","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6492-1288","authenticated-orcid":false,"given":"Hector","family":"Chinoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"key":"1033_CR1","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","volume":"61","author":"AGS Oldroyd","year":"2022","unstructured":"Oldroyd, A. G. S. et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology 61, 1760\u20131768 (2022).","journal-title":"Rheumatology"},{"key":"1033_CR2","doi-asserted-by":"publisher","first-page":"101486","DOI":"10.1016\/j.berh.2020.101486","volume":"34","author":"H Chinoy","year":"2020","unstructured":"Chinoy, H. & Lilleker, J. B. Pitfalls in the diagnosis of myositis. Best. Pract. Res. Clin. Rheumatol. 34, 101486 (2020).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"1033_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg, I. E. et al. Idiopathic inflammatory myopathies. Nat. Rev. Dis. Prim. 7, 86 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1033_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/13497413.2018.1481571","volume":"41","author":"S Barsotti","year":"2018","unstructured":"Barsotti, S. & Lundberg, I. E. Myositis an evolving spectrum of disease. Immunol. Med. 41, 46\u201354 (2018).","journal-title":"Immunol. Med."},{"key":"1033_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02570-9","volume":"17","author":"T Namsrai","year":"2022","unstructured":"Namsrai, T. et al. Diagnostic delay of myositis: an integrated systematic review. Orphanet J. Rare Dis. 17, 420 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"1033_CR6","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1097\/BOR.0000000000000441","volume":"29","author":"AL Mammen","year":"2017","unstructured":"Mammen, A. L. Which nonautoimmune myopathies are most frequently misdiagnosed as myositis? Curr. Opin. Rheumatol. 29, 618\u2013622 (2017).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1033_CR7","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3899\/jrheum.101149","volume":"38","author":"S Bernatsky","year":"2011","unstructured":"Bernatsky, S., Linehan, T. & Hanly, J. G. The accuracy of administrative data diagnoses of systemic autoimmune rheumatic diseases. J. Rheumatol. 38, 1612\u20131616 (2011).","journal-title":"J. Rheumatol."},{"key":"1033_CR8","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1111\/all.14468","volume":"75","author":"LK Tanno","year":"2020","unstructured":"Tanno, L. K. et al. Global implementation of the world health organization\u2019s International Classification of Diseases (ICD)-11: the allergic and hypersensitivity conditions model. Allergy 75, 2206\u20132218 (2020).","journal-title":"Allergy"},{"key":"1033_CR9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med. 292, 344\u2013347 (1975).","journal-title":"N. Engl. J. Med."},{"key":"1033_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (second of two parts). N. Engl. J. Med. 292, 403\u2013407 (1975).","journal-title":"N. Engl. J. Med."},{"key":"1033_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1212\/WNL.28.1.8","volume":"28","author":"S Carpenter","year":"1978","unstructured":"Carpenter, S., Karpati, G., Heller, I. & Eisen, A. Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology 28, 8\u201317 (1978).","journal-title":"Neurology"},{"key":"1033_CR12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ana.410380504","volume":"38","author":"RC Griggs","year":"1995","unstructured":"Griggs, R. C. et al. Inclusion body myositis and myopathies. Ann. Neurol. 38, 705\u2013713 (1995).","journal-title":"Ann. Neurol."},{"key":"1033_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk, J. E. et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands. Neuromuscul. Disord. 14, 337\u2013345 (2004).","journal-title":"Neuromuscul. Disord."},{"key":"1033_CR14","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.nmd.2020.02.003","volume":"30","author":"J Day","year":"2020","unstructured":"Day, J., Otto, S., Cash, K. & Limaye, V. Clinical and histological features of immune-mediated necrotising myopathy: a multi-centre South Australian cohort study. Neuromuscul. Disord. 30, 186\u2013199 (2020).","journal-title":"Neuromuscul. Disord."},{"key":"1033_CR15","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","volume":"16","author":"Y Allenbach","year":"2020","unstructured":"Allenbach, Y., Benveniste, O., Stenzel, W. & Boyer, O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat. Rev. Rheumatol. 16, 689\u2013701 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1033_CR16","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1093\/brain\/aww054","volume":"139","author":"Y Allenbach","year":"2016","unstructured":"Allenbach, Y. et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 139, 2131\u20132135 (2016).","journal-title":"Brain"},{"key":"1033_CR17","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","volume":"72","author":"CD Kassardjian","year":"2015","unstructured":"Kassardjian, C. D., Lennon, V. A., Alfugham, N. B., Mahler, M. & Milone, M. Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol. 72, 996\u20131003 (2015).","journal-title":"JAMA Neurol."},{"key":"1033_CR18","doi-asserted-by":"publisher","first-page":"670784","DOI":"10.3389\/fneur.2021.670784","volume":"12","author":"X Ma","year":"2021","unstructured":"Ma, X., Xu, L., Ji, S., Li, Y. & Bu, B. The clinicopathological distinction between seropositive and seronegative immune-mediated necrotizing myopathy in China. Front. Neurol. 12, 670784 (2021).","journal-title":"Front. Neurol."},{"key":"1033_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","volume":"28","author":"Y Allenbach","year":"2018","unstructured":"Allenbach, Y., Mammen, A. L., Benveniste, O. & Stenzel, W. & Immune-Mediated Necrotizing Myopathies Working Group. 224th ENMC International Workshop:: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016. Neuromuscul. Disord. 28, 87\u201399 (2018).","journal-title":"Neuromuscul. Disord."},{"key":"1033_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1136\/bmj.289.6438.151","volume":"289","author":"RM Bernstein","year":"1984","unstructured":"Bernstein, R. M. et al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br. Med. J. 289, 151\u2013152 (1984).","journal-title":"Br. Med. J."},{"key":"1033_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.berh.2016.04.007","volume":"30","author":"J Tieu","year":"2016","unstructured":"Tieu, J., Lundberg, I. E. & Limaye, V. Idiopathic inflammatory myositis. Best. Pract. Res. Clin. Rheumatol. 30, 149\u2013168 (2016).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"1033_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.semarthrit.2020.09.020","volume":"51","author":"AH Opinc","year":"2021","unstructured":"Opinc, A. H. & Makowska, J. S. Antisynthetase syndrome \u2014 much more than just a myopathy. Semin. Arthritis Rheum. 51, 72\u201383 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"1033_CR23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1177\/2397198320902667","volume":"5","author":"K Huang","year":"2020","unstructured":"Huang, K. & Aggarwal, R. Antisynthetase syndrome: a distinct disease spectrum. J. Scleroderma Relat. Disord. 5, 178\u2013191 (2020).","journal-title":"J. Scleroderma Relat. Disord."},{"key":"1033_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/nan.12519","volume":"45","author":"A Uruha","year":"2019","unstructured":"Uruha, A. et al. Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis. Neuropathol. Appl. Neurobiol. 45, 513\u2013522 (2019).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"1033_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s40478-014-0154-2","volume":"2","author":"J Aouizerate","year":"2014","unstructured":"Aouizerate, J. et al. Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy. Acta Neuropathol. Commun. 2, 154 (2014).","journal-title":"Acta Neuropathol. Commun."},{"key":"1033_CR26","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/1744666X.2022.2054803","volume":"18","author":"MC Dalakas","year":"2022","unstructured":"Dalakas, M. C. Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits. Expert. Rev. Clin. Immunol. 18, 413\u2013423 (2022).","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"1033_CR27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/0961203312468625","volume":"22","author":"LA Aguila","year":"2013","unstructured":"Aguila, L. A. et al. Overlap syndromes of idiopathic inflammatory myopathies with systemic lupus erythematosus, systemic sclerosis or rheumatoid arthritis. Lupus 22, 136 (2013).","journal-title":"Lupus"},{"key":"1033_CR28","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1055\/s-0042-112361","volume":"42","author":"AD Keck","year":"2017","unstructured":"Keck, A. D., Jaeger, V. K. & Walker, U. A. Myositis in systemic sclerosis, lupus erythematosus and Sjogren\u2019s syndrome. Aktuelle Rheumatol. 42, 310\u2013315 (2017).","journal-title":"Aktuelle Rheumatol."},{"key":"1033_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/BOR.0000000000000336","volume":"28","author":"JJ Paik","year":"2016","unstructured":"Paik, J. J. Myopathy in scleroderma and in other connective tissue diseases. Curr. Opin. Rheumatol. 28, 631\u2013635 (2016).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1033_CR30","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/BOR.0000000000000837","volume":"33","author":"V Leclair","year":"2021","unstructured":"Leclair, V., Notarnicola, A., Vencovsky, J. & Lundberg, I. E. Polymyositis: does it really exist as a distinct clinical subset? Curr. Opin. Rheumatol. 33, 537\u2013543 (2021).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1033_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","volume":"101","author":"Z Betteridge","year":"2019","unstructured":"Betteridge, Z. et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J. Autoimmun. 101, 48\u201355 (2019).","journal-title":"J. Autoimmun."},{"key":"1033_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.21037\/atm-20-5175","volume":"9","author":"LM Hodgkinson","year":"2021","unstructured":"Hodgkinson, L. M., Wu, T. T. & Fiorentino, D. F. Dermatomyositis autoantibodies: how can we maximize utility? Ann. Transl. Med. 9, 433 (2021).","journal-title":"Ann. Transl. Med."},{"key":"1033_CR33","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s10067-015-2935-9","volume":"34","author":"Z Chen","year":"2015","unstructured":"Chen, Z. et al. Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis\/dermatomyositis. Clin. Rheumatol. 34, 1627\u20131631 (2015).","journal-title":"Clin. Rheumatol."},{"key":"1033_CR34","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","volume":"14","author":"NJ McHugh","year":"2018","unstructured":"McHugh, N. J. & Tansley, S. L. Autoantibodies in myositis. Nat. Rev. Rheumatol. 14, 290\u2013302 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1033_CR35","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.nmd.2010.03.014","volume":"20","author":"O Benveniste","year":"2010","unstructured":"Benveniste, O. & Hilton-Jones, D. International workshop on inclusion body myositis held at the institute of myology, Paris, on 29 May 2009. Neuromuscul. Disord. 20, 414\u2013421 (2010).","journal-title":"Neuromuscul. Disord."},{"key":"1033_CR36","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas, M. C. & Hohlfeld, R. Polymyositis and dermatomyositis. Lancet 362, 971\u2013982 (2003).","journal-title":"Lancet"},{"key":"1033_CR37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/joim.12480","volume":"280","author":"D Hilton-Jones","year":"2016","unstructured":"Hilton-Jones, D. & Brady, S. Diagnostic criteria for inclusion body myositis. J. Intern. Med. 280, 52\u201362 (2016).","journal-title":"J. Intern. Med."},{"key":"1033_CR38","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","volume":"83","author":"TE Lloyd","year":"2014","unstructured":"Lloyd, T. E. et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology 83, 426\u2013433 (2014).","journal-title":"Neurology"},{"key":"1033_CR39","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","volume":"30","author":"AL Mammen","year":"2020","unstructured":"Mammen, A. L., Allenbach, Y., Stenzel, W., Benveniste, O. & ENMC 239th Workshop Study Group. 239th ENMC international workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14\u201316 December 2018. Neuromuscul. Disord. 30, 70\u201392 (2020).","journal-title":"Neuromuscul. Disord."},{"key":"1033_CR40","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","volume":"23","author":"MR Rose","year":"2013","unstructured":"Rose, M. R. & Group, E. I. W. 188th ENMC international workshop: inclusion body myositis, 2\u20134 December 2011, Naarden, The Netherlands. Neuromuscul. Disord. 23, 1044\u20131055 (2013).","journal-title":"Neuromuscul. Disord."},{"key":"1033_CR41","first-page":"668","volume":"22","author":"K Tanimoto","year":"1995","unstructured":"Tanimoto, K. et al. Classification criteria for polymyositis and dermatomyositis. J. Rheumatol. 22, 668\u2013674 (1995).","journal-title":"J. Rheumatol."},{"key":"1033_CR42","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/00002281-199711000-00008","volume":"9","author":"IN Targoff","year":"1997","unstructured":"Targoff, I. N., Miller, F. W., Medsger, T. A. Jr. & Oddis, C. V. Classification criteria for the idiopathic inflammatory myopathies. Curr. Opin. Rheumatol. 9, 527\u2013535 (1997).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1033_CR43","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/BOR.0000000000000643","volume":"31","author":"R Karasawa","year":"2019","unstructured":"Karasawa, R. & Jarvis, J. N. Using the tools of proteomics to understand the pathogenesis of idiopathic inflammatory myopathies. Curr. Opin. Rheumatol. 31, 617\u2013622 (2019).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1033_CR44","doi-asserted-by":"publisher","first-page":"886290","DOI":"10.3389\/fimmu.2022.886290","volume":"13","author":"JA Lamb","year":"2022","unstructured":"Lamb, J. A. The genetics of autoimmune myositis. Front. Immunol. 13, 886290 (2022).","journal-title":"Front. Immunol."},{"key":"1033_CR45","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/WCO.0000000000000855","volume":"33","author":"J Tanboon","year":"2020","unstructured":"Tanboon, J., Uruha, A., Stenzel, W. & Nishino, I. Where are we moving in the classification of idiopathic inflammatory myopathies? Curr. Opin. Neurol. 33, 590\u2013603 (2020).","journal-title":"Curr. Opin. Neurol."},{"key":"1033_CR46","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/art.40320","volume":"69","author":"IE Lundberg","year":"2017","unstructured":"Lundberg, I. E. et al. European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 69, 2271\u20132282 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1033_CR47","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3389\/fmed.2019.00326","volume":"6","author":"B Hervier","year":"2019","unstructured":"Hervier, B. & Uzunhan, Y. Inflammatory myopathy-related interstitial lung disease: from pathophysiology to treatment. Front. Med. 6, 326 (2019).","journal-title":"Front. Med."},{"key":"1033_CR48","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/acr2.11061","volume":"1","author":"Q Luu","year":"2019","unstructured":"Luu, Q., Day, J., Hall, A., Limaye, V. & Major, G. External validation and evaluation of adding MRI or extended myositis antibody panel to the 2017 EULAR\/ACR myositis classification criteria. ACR Open Rheumatol. 1, 462\u2013468 (2019).","journal-title":"ACR Open Rheumatol."},{"key":"1033_CR49","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/01.bor.0000434667.55020.e1","volume":"25","author":"IE Lundberg","year":"2013","unstructured":"Lundberg, I. E. & Svensson, J. Registries in idiopathic inflammatory myopathies. Curr. Opin. Rheumatol. 25, 729\u2013734 (2013).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1033_CR50","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","volume":"54","author":"A Meyer","year":"2014","unstructured":"Meyer, A. et al. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology 54, 50\u201363 (2014).","journal-title":"Rheumatology"},{"key":"1033_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-11-98","volume":"11","author":"I Anagnostopoulos","year":"2010","unstructured":"Anagnostopoulos, I. et al. The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet. Disord. 11, 98 (2010).","journal-title":"BMC Musculoskelet. Disord."},{"key":"1033_CR52","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10067-015-3148-y","volume":"35","author":"F Julian-Santiago","year":"2016","unstructured":"Julian-Santiago, F., Garcia-Garcia, C., Garcia-Olivera, I., Goycochea-Robles, M. V. & Pelaez-Ballestas, I. Epidemiology of rheumatic diseases in Mixtec and Chontal indigenous communities in Mexico: a cross-sectional community-based study. Clin. Rheumatol. 35, 35\u201342 (2016).","journal-title":"Clin. Rheumatol."},{"key":"1033_CR53","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2991\/jegh.k.190920.001","volume":"9","author":"DS Tolentino","year":"2019","unstructured":"Tolentino, D. S., de Oliveira, C. M. & de Assis, E. M. Population-based study of 24 autoimmune diseases carried out in a Brazilian microregion. J. Epidemiol. Glob. Health 9, 243\u2013251 (2019).","journal-title":"J. Epidemiol. Glob. Health"},{"key":"1033_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2007.05.002","volume":"29","author":"WW Eaton","year":"2007","unstructured":"Eaton, W. W., Rose, N. R., Kalaydjian, A., Pedersen, M. G. & Mortensen, P. B. Epidemiology of autoimmune diseases in Denmark. J. Autoimmun. 29, 1\u20139 (2007).","journal-title":"J. Autoimmun."},{"key":"1033_CR55","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s42466-022-00226-4","volume":"4","author":"M Pawlitzki","year":"2022","unstructured":"Pawlitzki, M. et al. Myositis in Germany: epidemiological insights over 15 years from 2005 to 2019. Neurol. Res. Pract. 4, 62 (2022).","journal-title":"Neurol. Res. Pract."},{"key":"1033_CR56","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2019.34.e55","volume":"34","author":"SK Cho","year":"2019","unstructured":"Cho, S. K. et al. Incidence and prevalence of idiopathic inflammatory myopathies in Korea: a nationwide population-based study. J. Korean Med. Sci. 34, e55 (2019).","journal-title":"J. Korean Med. Sci."},{"key":"1033_CR57","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/mus.23302","volume":"45","author":"DE Furst","year":"2012","unstructured":"Furst, D. E., Amato, A. A., Iorga, S. R., Gajria, K. & Fernandes, A. W. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve 45, 676\u2013683 (2012).","journal-title":"Muscle Nerve"},{"key":"1033_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-13-103","volume":"13","author":"KE Smoyer-Tomic","year":"2012","unstructured":"Smoyer-Tomic, K. E., Amato, A. A. & Fernandes, A. W. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculoskelet. Disord. 13, 103 (2012).","journal-title":"BMC Musculoskelet. Disord."},{"key":"1033_CR59","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1001\/jamadermatol.2022.3112","volume":"158","author":"CM Bolender","year":"2022","unstructured":"Bolender, C. M. et al. Incidence of dermatomyositis in a nationwide cohort study of US veterans. JAMA Dermatol. 158, 1321\u20131323 (2022).","journal-title":"JAMA Dermatol."},{"key":"1033_CR60","doi-asserted-by":"publisher","first-page":"E552","DOI":"10.1097\/RHU.0000000000001736","volume":"28","author":"M Essouma","year":"2022","unstructured":"Essouma, M., Noubiap, J. J., Singwe-Ngandeu, M. & Hachulla, E. Epidemiology of idiopathic inflammatory myopathies in Africa: a contemporary systematic review. J. Clin. Rheumatol. 28, E552\u2013E562 (2022).","journal-title":"J. Clin. Rheumatol."},{"key":"1033_CR61","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1479-8077.2007.00267.x","volume":"10","author":"V Limaye","year":"2007","unstructured":"Limaye, V. et al. The epidemiology of dermatomyositis in South Australia. APLAR J. Rheumatol. 10, 94\u2013100 (2007).","journal-title":"APLAR J. Rheumatol."},{"key":"1033_CR62","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10067-018-4237-5","volume":"38","author":"J Ostrovr\u0161nik","year":"2019","unstructured":"Ostrovr\u0161nik, J. et al. The incidence of idiopathic inflammatory myopathies in the adult Slovenian population. Clin. Rheumatol. 38, 279\u2013283 (2019).","journal-title":"Clin. Rheumatol."},{"key":"1033_CR63","doi-asserted-by":"publisher","first-page":"rky035","DOI":"10.1093\/rap\/rky035","volume":"2","author":"MJS Parker","year":"2018","unstructured":"Parker, M. J. S. et al. Increasing incidence of adult idiopathic inflammatory myopathies in the City of Salford, UK: a 10-year epidemiological study. Rheumatol. Adv. Pract. 2, rky035 (2018).","journal-title":"Rheumatol. Adv. Pract."},{"key":"1033_CR64","first-page":"1094","volume":"26","author":"M Patrick","year":"1999","unstructured":"Patrick, M., Buchbinder, R., Jolley, D., Dennett, X. & Buchanan, R. Incidence of inflammatory myopathies in Victoria, Australia, and evidence of spatial clustering. J. Rheumatol. 26, 1094\u20131100 (1999).","journal-title":"J. Rheumatol."},{"key":"1033_CR65","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.semarthrit.2013.06.001","volume":"43","author":"LC See","year":"2013","unstructured":"See, L. C., Kuo, C. F., Chou, I. J., Chiou, M. J. & Yu, K. H. Sex- and age-specific incidence of autoimmune rheumatic diseases in the Chinese population: a Taiwan population-based study. Semin. Arthritis Rheumatism 43, 381\u2013386 (2013).","journal-title":"Semin. Arthritis Rheumatism"},{"key":"1033_CR66","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/acr.21820","volume":"65","author":"KH Yu","year":"2013","unstructured":"Yu, K. H., See, L. C., Kuo, C. F., Chou, I. J. & Chou, M. J. Prevalence and incidence in patients with autoimmune rheumatic diseases: a nationwide population-based study in Taiwan. Arthritis Care Res. 65, 244\u2013250 (2013).","journal-title":"Arthritis Care Res."},{"key":"1033_CR67","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1756-185X.2011.01669.x","volume":"16","author":"JA Tan","year":"2013","unstructured":"Tan, J. A. et al. Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30-year epidemiologic study of histology-proven cases. Int. J. Rheum. Dis. 16, 331\u2013338 (2013).","journal-title":"Int. J. Rheum. Dis."},{"key":"1033_CR68","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S0002-9343(70)80006-7","volume":"48","author":"TA Medsger Jr","year":"1970","unstructured":"Medsger, T. A. Jr, Dawson, W. N. Jr & Masi, A. T. The epidemiology of polymyositis. Am. J. Med. 48, 715\u2013723 (1970).","journal-title":"Am. J. Med."},{"key":"1033_CR69","first-page":"197","volume":"16","author":"J Benbassat","year":"1980","unstructured":"Benbassat, J., Geffel, D. & Zlotnick, A. Epidemiology of polymyositis-dermatomyositis in Israel, 1960\u201376. Isr. J. Med. Sci. 16, 197\u2013200 (1980).","journal-title":"Isr. J. Med. Sci."},{"key":"1033_CR70","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/rheumatology\/kew503","volume":"56","author":"J Svensson","year":"2017","unstructured":"Svensson, J., Arkema, E. V., Lundberg, I. E. & Holmqvist, M. Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study. Rheumatology 56, 802\u2013810 (2017).","journal-title":"Rheumatology"},{"key":"1033_CR71","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/j.1365-2133.2011.10595.x","volume":"165","author":"CF Kuo","year":"2011","unstructured":"Kuo, C. F. et al. Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br. J. Dermatol. 165, 1273\u20131279 (2011).","journal-title":"Br. J. Dermatol."},{"key":"1033_CR72","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/acr.24786","volume":"75","author":"VL Kronzer","year":"2023","unstructured":"Kronzer, V. L. et al. Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study. Arthritis Care Res. 75, 348\u2013355 (2023).","journal-title":"Arthritis Care Res."},{"key":"1033_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261983","volume":"16","author":"IM Carey","year":"2021","unstructured":"Carey, I. M. et al. Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: a retrospective study using primary care data. PLoS One 16, e0261983 (2021).","journal-title":"PLoS One"},{"key":"1033_CR74","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1212\/WNL.55.9.1385","volume":"55","author":"UA Badrising","year":"2000","unstructured":"Badrising, U. A. et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 55, 1385\u20131387 (2000).","journal-title":"Neurology"},{"key":"1033_CR75","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/ene.12627","volume":"22","author":"GC Dobloug","year":"2015","unstructured":"Dobloug, G. C. et al. High prevalence of inclusion body myositis in Norway; a population-based clinical epidemiology study. Eur. J. Neurol. 22, 672\u2013e641 (2015).","journal-title":"Eur. J. Neurol."},{"key":"1033_CR76","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/00005792-200109000-00006","volume":"80","author":"KJ Felice","year":"2001","unstructured":"Felice, K. J. & North, W. A. Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period. Medicine 80, 320\u2013327 (2001).","journal-title":"Medicine"},{"key":"1033_CR77","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1212\/WNL.0000000000003504","volume":"88","author":"S Lefter","year":"2017","unstructured":"Lefter, S., Hardiman, O. & Ryan, A. M. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology 88, 304\u2013313 (2017).","journal-title":"Neurology"},{"key":"1033_CR78","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ana.26412","volume":"92","author":"U Lindgren","year":"2022","unstructured":"Lindgren, U., Pullerits, R., Lindberg, C. & Oldfors, A. Epidemiology, survival, and clinical characteristics of inclusion body myositis. Ann. Neurol. 92, 201\u2013212 (2022).","journal-title":"Ann. Neurol."},{"key":"1033_CR79","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/(SICI)1097-4598(200006)23:6<970::AID-MUS20>3.0.CO;2-I","volume":"23","author":"BA Phillips","year":"2000","unstructured":"Phillips, B. A., Zilko, P. J. & Mastaglia, F. L. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve 23, 970\u2013972 (2000).","journal-title":"Muscle Nerve"},{"key":"1033_CR80","first-page":"34","volume":"30","author":"P Serdaroglu Oflazer","year":"2011","unstructured":"Serdaroglu Oflazer, P., Deymeer, F. & Parman, Y. Sporadic-inclusion body myositis (s-IBM) is not so prevalent in Istanbul\/Turkey: a muscle biopsy based survey. Acta Myol. 30, 34\u201336 (2011).","journal-title":"Acta Myol."},{"key":"1033_CR81","doi-asserted-by":"publisher","first-page":"e2653","DOI":"10.1212\/WNL.0000000000012004","volume":"96","author":"S Shelly","year":"2021","unstructured":"Shelly, S. et al. Epidemiology and natural history of inclusion body myositis: a 40-year population-based study. Neurology 96, e2653\u2013e2661 (2021).","journal-title":"Neurology"},{"key":"1033_CR82","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/1756-185X.13902","volume":"23","author":"A Balakrishnan","year":"2020","unstructured":"Balakrishnan, A., Aggarwal, R., Agarwal, V. & Gupta, L. Inclusion body myositis in the rheumatology clinic. Int. J. Rheum. Dis. 23, 1126\u20131135 (2020).","journal-title":"Int. J. Rheum. Dis."},{"key":"1033_CR83","first-page":"445","volume":"35","author":"FC Wilson","year":"2008","unstructured":"Wilson, F. C., Ytterberg, S. R., St Sauver, J. L. & Reed, A. M. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J. Rheumatol. 35, 445\u2013447 (2008).","journal-title":"J. Rheumatol."},{"key":"1033_CR84","first-page":"390","volume":"56","author":"T Arkachaisri","year":"2017","unstructured":"Arkachaisri, T. et al. Paediatric rheumatology clinic population in Southeast Asia: are we different? Rheumatology 56, 390\u2013398 (2017).","journal-title":"Rheumatology"},{"key":"1033_CR85","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","volume":"17","author":"MRW Barber","year":"2021","unstructured":"Barber, M. R. W. et al. Global epidemiology of systemic lupus erythematosus. Nat. Rev. Rheumatol. 17, 515\u2013532 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1033_CR86","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3899\/jrheum.180042","volume":"46","author":"H Al-Sheikh","year":"2019","unstructured":"Al-Sheikh, H., Ahmad, Z. & Johnson, S. R. Ethnic variations in systemic sclerosis disease manifestations, internal organ involvement, and mortality. J. Rheumatol. 46, 1103\u20131108 (2019).","journal-title":"J. Rheumatol."},{"key":"1033_CR87","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/art.11122","volume":"49","author":"EP Mendez","year":"2003","unstructured":"Mendez, E. P. et al. US incidence of juvenile dermatomyositis, 1995\u20131998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Care Res. 49, 300\u2013305 (2003).","journal-title":"Arthritis Care Res."},{"key":"1033_CR88","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1111\/jpc.15595","volume":"57","author":"A Concannon","year":"2021","unstructured":"Concannon, A. & Han, D. Y. Incidence, severity and clinical manifestations of juvenile dermatomyositis among Maori and Pacific Island compared to European children. J. Paediatrics Child. Health 57, 1881\u20131885 (2021).","journal-title":"J. Paediatrics Child. Health"},{"key":"1033_CR89","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/imj.13816","volume":"48","author":"J Day","year":"2018","unstructured":"Day, J. & Limaye, V. Over-representation of statin-associated necrotising myopathy in patients of Aboriginal and Torres Strait Islander heritage. Intern. Med. J. 48, 749\u2013751 (2018).","journal-title":"Intern. Med. J."},{"key":"1033_CR90","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/imj.13575","volume":"48","author":"M Woolley","year":"2018","unstructured":"Woolley, M., Stebbings, S. & Highton, J. Statin-associated immune-mediated necrotising myopathy: a New Zealand case series showing possible overrepresentation in Pacific Islanders. Intern. Med. J. 48, 32\u201336 (2018).","journal-title":"Intern. Med. J."},{"key":"1033_CR91","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1093\/rheumatology\/keaa337","volume":"60","author":"RM Close","year":"2021","unstructured":"Close, R. M. et al. Potential implications of six American Indian patients with myopathy, statin exposure and anti-HMGCR antibodies. Rheumatology 60, 692\u2013698 (2021).","journal-title":"Rheumatology"},{"key":"1033_CR92","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1056\/NEJMra1515161","volume":"374","author":"AL Mammen","year":"2016","unstructured":"Mammen, A. L. Statin-associated autoimmune myopathy. N. Engl. J. Med. 374, 664\u2013669 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1033_CR93","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/imj.13815","volume":"48","author":"MC Woolley","year":"2018","unstructured":"Woolley, M. C. & Stebbings, S. Author reply. Intern. Med. J. 48, 751\u2013752 (2018).","journal-title":"Intern. Med. J."},{"key":"1033_CR94","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.41632","volume":"73","author":"PM Izmirly","year":"2021","unstructured":"Izmirly, P. M. et al. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus registries. Arthritis Rheumatol. 73, 991\u2013996 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1033_CR95","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1177\/0961203316686701","volume":"26","author":"E Ly","year":"2017","unstructured":"Ly, E., Thein, H. & Lam Po Tang, M. Retrospective review of lupus nephritis in a New Zealand multi-ethnic cohort. Lupus 26, 893\u2013897 (2017).","journal-title":"Lupus"},{"key":"1033_CR96","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/imj.14710","volume":"50","author":"A Nigam","year":"2020","unstructured":"Nigam, A. et al. Lupus nephritis in indigenous Australians: a single-centre study. Intern. Med. J. 50, 830\u2013837 (2020).","journal-title":"Intern. Med. J."},{"key":"1033_CR97","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/imj.12577","volume":"44","author":"M Gracey","year":"2014","unstructured":"Gracey, M. Why closing the Aboriginal health gap is so elusive. Intern. Med. J. 44, 1141\u20131143 (2014).","journal-title":"Intern. Med. J."},{"key":"1033_CR98","first-page":"738","volume":"7","author":"J Stoneman","year":"2007","unstructured":"Stoneman, J. & Taylor, S. J. Improving access to medicines in urban, regional and rural Aboriginal communities \u2014 is expansion of Section 100 the answer? Rural. Remote. Health 7, 738 (2007).","journal-title":"Rural. Remote. Health"},{"key":"1033_CR99","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5694\/mja2.50327","volume":"211","author":"KA Thurber","year":"2019","unstructured":"Thurber, K. A. & Bell, K. J. Socio-economic disadvantage and cardiovascular risk factors in young Aboriginal and Torres Strait Islander Australians. Med. J. Aust. 211, 259\u2013260 (2019).","journal-title":"Med. J. Aust."},{"key":"1033_CR100","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3109\/14397595.2013.844308","volume":"24","author":"A Ohta","year":"2014","unstructured":"Ohta, A., Nagai, M., Nishina, M., Tomimitsu, H. & Kohsaka, H. Prevalence and incidence of polymyositis and dermatomyositis in Japan. Mod. Rheumatol. 24, 477\u2013480 (2014).","journal-title":"Mod. Rheumatol."},{"key":"1033_CR101","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/j.1365-2133.2007.08055.x","volume":"157","author":"P Gerami","year":"2007","unstructured":"Gerami, P., Walling, H. W., Lewis, J., Doughty, L. & Sontheimer, R. D. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br. J. Dermatol. 157, 637\u2013644 (2007).","journal-title":"Br. J. Dermatol."},{"key":"1033_CR102","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archdermatol.2009.328","volume":"146","author":"MJ Bendewald","year":"2010","unstructured":"Bendewald, M. J., Wetter, D. A., Li, X. & Davis, M. D. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch. Dermatol. 146, 26\u201330 (2010).","journal-title":"Arch. Dermatol."},{"key":"1033_CR103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189840","volume":"12","author":"J Greenfield","year":"2017","unstructured":"Greenfield, J. et al. A comparison of health-related quality of life (HRQoL) across four systemic autoimmune rheumatic diseases (SARDs). PLoS One 12, e0189840 (2017).","journal-title":"PLoS One"},{"key":"1033_CR104","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1007\/s00415-014-7313-z","volume":"261","author":"J van de Vlekkert","year":"2014","unstructured":"van de Vlekkert, J., Hoogendijk, J. E. & de Visser, M. Long-term follow-up of 62 patients with myositis. J. Neurol. 261, 992\u2013998 (2014).","journal-title":"J. Neurol."},{"key":"1033_CR105","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-060312","volume":"12","author":"T Namsrai","year":"2022","unstructured":"Namsrai, T. et al. Diagnostic delay of myositis: protocol for an integrated systematic review. BMJ Open\u00a012, e060312 (2022).","journal-title":"BMJ Open"},{"key":"1033_CR106","doi-asserted-by":"publisher","first-page":"e1005","DOI":"10.1016\/S2468-2667(22)00203-1","volume":"7","author":"J Gong","year":"2022","unstructured":"Gong, J. et al. Nowcasting and forecasting the care needs of the older population in China: analysis of data from the China Health and Retirement Longitudinal Study (CHARLS). Lancet Public Health 7, e1005\u2013e1013 (2022).","journal-title":"Lancet Public Health"},{"key":"1033_CR107","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41584-022-00768-6","volume":"18","author":"M van Onna","year":"2022","unstructured":"van Onna, M. & Boonen, A. Challenges in the management of older patients with inflammatory rheumatic diseases. Nat. Rev. Rheumatol. 18, 326\u2013334 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1033_CR108","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3899\/jrheum.101083","volume":"38","author":"S Bernatsky","year":"2011","unstructured":"Bernatsky, S. et al. Healthcare costs of inflammatory myopathies. J. Rheumatol. 38, 885\u2013888 (2011).","journal-title":"J. Rheumatol."},{"key":"1033_CR109","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/mus.23384","volume":"46","author":"DE Furst","year":"2012","unstructured":"Furst, D. E., Amato, A. A., Iorga, S. R., Bancroft, T. & Fernandes, A. W. Medical costs and health-care resource use in patients with inflammatory myopathies in an insured population. Muscle Nerve 46, 496\u2013505 (2012).","journal-title":"Muscle Nerve"},{"key":"1033_CR110","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.semarthrit.2021.07.016","volume":"51","author":"V Leclair","year":"2021","unstructured":"Leclair, V. et al. Distribution and trajectory of direct and indirect costs of idiopathic inflammatory myopathies. Semin. Arthritis Rheum. 51, 983\u2013988 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"1033_CR111","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3233\/WOR-152127","volume":"53","author":"M Regardt","year":"2015","unstructured":"Regardt, M., Welin Henriksson, E., Sandqvist, J., Lundberg, I. E. & Schult, M. L. Work ability in patients with polymyositis and dermatomyositis: an explorative and descriptive study. Work 53, 265\u2013277 (2015).","journal-title":"Work"},{"key":"1033_CR112","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/1756-185X.14120","volume":"24","author":"A Xu","year":"2021","unstructured":"Xu, A., Sun, C., Metcalf, R. & Limaye, V. Health-related quality of life and work impairment in idiopathic inflammatory myopathies in South Australia. Int. J. Rheum. Dis. 24, 809\u2013814 (2021).","journal-title":"Int. J. Rheum. Dis."},{"key":"1033_CR113","first-page":"1424","volume":"26","author":"L Christopher-Stine","year":"2020","unstructured":"Christopher-Stine, L. et al. Patient-reported dermatomyositis and polymyositis flare symptoms are associated with disability, productivity loss, and health care resource use. J. Manag. Care Spec. Pharm. 26, 1424\u20131433 (2020).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"1033_CR114","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0022-510X(75)90115-X","volume":"26","author":"D Riddoch","year":"1975","unstructured":"Riddoch, D. & Morgan-Hughes, J. A. Prognosis in adult polymyositis. J. Neurol. Sci. 26, 71\u201380 (1975).","journal-title":"J. Neurol. Sci."},{"key":"1033_CR115","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1136\/ard.2005.045690","volume":"65","author":"IM Bronner","year":"2006","unstructured":"Bronner, I. M. et al. Long-term outcome in polymyositis and dermatomyositis. Ann. Rheum. Dis. 65, 1456\u20131461 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"1033_CR116","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/annrheumdis-2017-211402","volume":"77","author":"GC Dobloug","year":"2018","unstructured":"Dobloug, G. C., Svensson, J., Lundberg, I. E. & Holmqvist, M. Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. Ann. Rheum. Dis. 77, 40\u201347 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1033_CR117","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/rheumatology\/41.1.22","volume":"41","author":"SM Sultan","year":"2002","unstructured":"Sultan, S. M., Ioannou, Y., Moss, K. & Isenberg, D. A. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology 41, 22\u201326 (2002).","journal-title":"Rheumatology"},{"key":"1033_CR118","first-page":"2230","volume":"28","author":"I Marie","year":"2001","unstructured":"Marie, I. et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J. Rheumatol. 28, 2230\u20132237 (2001).","journal-title":"J. Rheumatol."},{"key":"1033_CR119","first-page":"820","volume":"34","author":"M Amaral Silva","year":"2016","unstructured":"Amaral Silva, M., Cogollo, E. & Isenberg, D. A. Why do patients with myositis die? A retrospective analysis of a single-centre cohort. Clin. Exp. Rheumatol. 34, 820\u2013826 (2016).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1033_CR120","doi-asserted-by":"publisher","first-page":"801078","DOI":"10.3389\/fmed.2021.801078","volume":"8","author":"A Hocevar","year":"2021","unstructured":"Hocevar, A. et al. Survival of patients with idiopathic inflammatory myopathies in Slovenia. Front. Med. 8, 801078 (2021).","journal-title":"Front. Med."},{"key":"1033_CR121","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1445-5994.2010.02406.x","volume":"42","author":"V Limaye","year":"2012","unstructured":"Limaye, V., Hakendorf, P., Woodman, R. J., Blumbergs, P. & Roberts-Thomson, P. Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. Intern. Med. J. 42, 191\u2013198 (2012).","journal-title":"Intern. Med. J."},{"key":"1033_CR122","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00296-017-3799-x","volume":"37","author":"L Nuno-Nuno","year":"2017","unstructured":"Nuno-Nuno, L. et al. Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain. Rheumatol. Int. 37, 1853\u20131861 (2017).","journal-title":"Rheumatol. Int."},{"key":"1033_CR123","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.autrev.2014.08.023","volume":"13","author":"MG Danieli","year":"2014","unstructured":"Danieli, M. G. et al. Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. Autoimmun. Rev. 13, 1048\u20131054 (2014).","journal-title":"Autoimmun. Rev."},{"key":"1033_CR124","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/brain\/98.4.637","volume":"98","author":"R DeVere","year":"1975","unstructured":"DeVere, R. & Bradley, W. G. Polymyositis: its presentation, morbidity and mortality. Brain 98, 637\u2013666 (1975).","journal-title":"Brain"},{"key":"1033_CR125","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/art.1780140210","volume":"14","author":"TA Medsger Jr.","year":"1971","unstructured":"Medsger, T. A. Jr., Robinson, H. & Masi, A. T. Factors affecting survivorship in polymyositis. A life-table study of 124 patients. Arthritis Rheum. 14, 249\u2013258 (1971).","journal-title":"Arthritis Rheum."},{"key":"1033_CR126","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s10067-018-4353-2","volume":"38","author":"T Cobo-Ibanez","year":"2019","unstructured":"Cobo-Ibanez, T. et al. Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. Clin. Rheumatol. 38, 803\u2013815 (2019).","journal-title":"Clin. Rheumatol."},{"key":"1033_CR127","doi-asserted-by":"publisher","first-page":"R22","DOI":"10.1186\/ar3704","volume":"14","author":"E Schiopu","year":"2012","unstructured":"Schiopu, E., Phillips, K., MacDonald, P. M., Crofford, L. J. & Somers, E. C. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res. Ther. 14, R22 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"1033_CR128","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/08916930600622603","volume":"39","author":"C Torres","year":"2006","unstructured":"Torres, C. et al. Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 39, 205\u2013215 (2006).","journal-title":"Autoimmunity"},{"key":"1033_CR129","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/01.md.0000109755.65914.5e","volume":"83","author":"K Danko","year":"2004","unstructured":"Danko, K., Ponyi, A., Constantin, T., Borgulya, G. & Szegedi, G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine 83, 35\u201342 (2004).","journal-title":"Medicine"},{"key":"1033_CR130","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","volume":"194","author":"C Johnson","year":"2016","unstructured":"Johnson, C. et al. Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease. Lung 194, 733\u2013737 (2016).","journal-title":"Lung"},{"key":"1033_CR131","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","volume":"73","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal, R. et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann. Rheum. Dis. 73, 227\u2013232 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1033_CR132","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s10067-015-3023-x","volume":"34","author":"J Rojas-Serrano","year":"2015","unstructured":"Rojas-Serrano, J. et al. Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD). Clin. Rheumatol. 34, 1563\u20131569 (2015).","journal-title":"Clin. Rheumatol."},{"key":"1033_CR133","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/BOR.0000000000000663","volume":"31","author":"M Gasparotto","year":"2019","unstructured":"Gasparotto, M. et al. Pulmonary involvement in antisynthetase syndrome. Curr. Opin. Rheumatol. 31, 603\u2013610 (2019).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1033_CR134","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","volume":"11","author":"I Marie","year":"2012","unstructured":"Marie, I. et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome. Autoimmun. Rev. 11, 739\u2013745 (2012).","journal-title":"Autoimmun. Rev."},{"key":"1033_CR135","doi-asserted-by":"publisher","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","volume":"12","author":"A Nombel","year":"2021","unstructured":"Nombel, A., Fabien, N. & Coutant, F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front. Immunol. 12, 773352 (2021).","journal-title":"Front. Immunol."},{"key":"1033_CR136","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1093\/rheumatology\/keac094","volume":"61","author":"J So","year":"2022","unstructured":"So, J. et al. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis. Rheumatology 61, 4437\u20134444 (2022).","journal-title":"Rheumatology"},{"key":"1033_CR137","doi-asserted-by":"publisher","first-page":"908365","DOI":"10.3389\/fmed.2022.908365","volume":"9","author":"Q Niu","year":"2022","unstructured":"Niu, Q. et al. A new predictive model for the prognosis of MDA5+ DM-ILD. Front. Med. 9, 908365 (2022).","journal-title":"Front. Med."},{"key":"1033_CR138","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01705-8","volume":"16","author":"Q Yang","year":"2021","unstructured":"Yang, Q. et al. Initial predictors for short-term prognosis in anti-melanoma differentiation-associated protein-5 positive patients. Orphanet J. Rare Dis. 16, 58 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"1033_CR139","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.2147\/IJGM.S327751","volume":"14","author":"J Zhou","year":"2021","unstructured":"Zhou, J. et al. Evaluation of prognostic factors in anti-MDA5 antibody-positive patients in Chongqing, China: a retrospective study. Int. J. Gen. Med. 14, 4775\u20134781 (2021).","journal-title":"Int. J. Gen. Med."},{"key":"1033_CR140","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"H Tsuji","year":"2020","unstructured":"Tsuji, H. et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 72, 488\u2013498 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1033_CR141","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1136\/annrheumdis-2021-219914","volume":"80","author":"WI Che","year":"2021","unstructured":"Che, W. I. et al. Familial aggregation and heritability: a nationwide family-based study of idiopathic inflammatory myopathies. Ann. Rheum. Dis. 80, 1461\u20131466 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1033_CR142","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/joim.13573","volume":"293","author":"WI Che","year":"2023","unstructured":"Che, W. I. et al. Familial autoimmunity in patients with idiopathic inflammatory myopathies. J. Intern. Med. 293, 200\u2013211 (2023).","journal-title":"J. Intern. Med."},{"key":"1033_CR143","doi-asserted-by":"publisher","unstructured":"Rothwell, S. et al. Genome-wide imputation identifies novel associations and localises signals in idiopathic inflammatory myopathies. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.42434 (2022).","DOI":"10.1002\/art.42434"},{"key":"1033_CR144","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/BOR.0000000000000652","volume":"31","author":"S Rothwell","year":"2019","unstructured":"Rothwell, S., Chinoy, H. & Lamb, J. A. Genetics of idiopathic inflammatory myopathies: insights into disease pathogenesis. Curr. Opin. Rheumatol. 31, 611\u2013616 (2019).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1033_CR145","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1136\/annrheumdis-2015-208119","volume":"75","author":"S Rothwell","year":"2016","unstructured":"Rothwell, S. et al. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann. Rheum. Dis. 75, 1558\u20131566 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1033_CR146","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/tan.13305","volume":"92","author":"CM Gambino","year":"2018","unstructured":"Gambino, C. M., Aiello, A., Accardi, G., Caruso, C. & Candore, G. Autoimmune diseases and 8.1 ancestral haplotype: an update. HLA 92, 137\u2013143 (2018).","journal-title":"HLA"},{"key":"1033_CR147","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/art.40045","volume":"69","author":"S Rothwell","year":"2017","unstructured":"Rothwell, S. et al. Immune-array analysis in sporadic inclusion body myositis reveals HLA-DRB1 amino acid heterogeneity across the myositis spectrum. Arthritis Rheumatol. 69, 1090\u20131099 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1033_CR148","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/annrheumdis-2019-215046","volume":"78","author":"S Rothwell","year":"2019","unstructured":"Rothwell, S. et al. Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann. Rheum. Dis. 78, 996\u20131002 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1033_CR149","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","volume":"60","author":"AGS Oldroyd","year":"2021","unstructured":"Oldroyd, A. G. S. et al. A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. Rheumatology 60, 2615\u20132628 (2021).","journal-title":"Rheumatology"},{"key":"1033_CR150","doi-asserted-by":"publisher","first-page":"5513544","DOI":"10.1155\/2021\/5513544","volume":"2021","author":"D Kwiatkowska","year":"2021","unstructured":"Kwiatkowska, D. & Reich, A. The significance of autoantibodies in juvenile dermatomyositis. Biomed. Res. Int. 2021, 5513544 (2021).","journal-title":"Biomed. Res. Int."},{"key":"1033_CR151","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jacc.2016.04.037","volume":"68","author":"P Basharat","year":"2016","unstructured":"Basharat, P. et al. Statin-induced anti-HMGCR-associated myopathy. J. Am. Coll. Cardiol. 68, 234\u2013235 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1033_CR152","first-page":"D783","volume":"48","author":"FF Gonzalez-Galarza","year":"2020","unstructured":"Gonzalez-Galarza, F. F. et al. Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools. Nucleic Acids Res. 48, D783\u2013D788 (2020).","journal-title":"Nucleic Acids Res."},{"key":"1033_CR153","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/mus.24541","volume":"52","author":"V Limaye","year":"2015","unstructured":"Limaye, V. et al. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve 52, 196\u2013203 (2015).","journal-title":"Muscle Nerve"},{"key":"1033_CR154","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/art.42434","volume":"75","author":"S Rothwell","year":"2022","unstructured":"Rothwell, S. et al. Identification of novel associations and localization of signals in idiopathic inflammatory myopathies using genome-wide imputation. Arthritis Rheumatol. 75, 1021\u20131027 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1033_CR155","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"SEARCH Collaborative Group","year":"2008","unstructured":"SEARCH Collaborative Group et al. SLCO1B1 variants and statin-induced myopathy \u2014 a genomewide study. N. Engl. J. Med. 359, 789\u2013799 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1033_CR156","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/cpt.1557","volume":"106","author":"DF Carr","year":"2019","unstructured":"Carr, D. F. et al. Genomewide association study of statin-induced myopathy in patients recruited using the UK clinical practice research datalink. Clin. Pharmacol. Ther. 106, 1353\u20131361 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1033_CR157","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/annrheumdis-2011-200182","volume":"71","author":"H Chinoy","year":"2012","unstructured":"Chinoy, H. et al. Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. Ann. Rheum. Dis. 71, 961\u2013965 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1033_CR158","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.semarthrit.2018.02.003","volume":"48","author":"A Schiffenbauer","year":"2018","unstructured":"Schiffenbauer, A. et al. The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis. Semin. Arthritis Rheum. 48, 504\u2013512 (2018).","journal-title":"Semin. Arthritis Rheum."},{"key":"1033_CR159","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1136\/ard.2005.041079","volume":"65","author":"SP Linn-Rasker","year":"2006","unstructured":"Linn-Rasker, S. P. et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann. Rheum. Dis. 65, 366\u2013371 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"1033_CR160","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1002\/acr.21671","volume":"64","author":"AL Mammen","year":"2012","unstructured":"Mammen, A. L. et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res. 64, 1233\u20131237 (2012).","journal-title":"Arthritis Care Res."},{"key":"1033_CR161","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1002\/art.22205","volume":"54","author":"TP O\u2019Hanlon","year":"2006","unstructured":"O\u2019Hanlon, T. P. et al. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum. 54, 3670\u20133681 (2006).","journal-title":"Arthritis Rheum."},{"key":"1033_CR162","first-page":"1768","volume":"31","author":"T Furuya","year":"2004","unstructured":"Furuya, T. et al. Immunogenetic features in 120 Japanese patients with idiopathic inflammatory myopathy. J. Rheumatol. 31, 1768\u20131774 (2004).","journal-title":"J. Rheumatol."},{"key":"1033_CR163","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.semarthrit.2019.03.005","volume":"49","author":"EH Kang","year":"2019","unstructured":"Kang, E. H. et al. Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients. Semin. Arthritis Rheum. 49, 283\u2013287 (2019).","journal-title":"Semin. Arthritis Rheum."},{"key":"1033_CR164","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1093\/rheumatology\/kead006","volume":"62","author":"L Guo","year":"2023","unstructured":"Guo, L. et al. WDFY4 polymorphisms in Chinese patients with anti-MDA5 dermatomyositis is associated with rapid progressive interstitial lung disease. Rheumatology 62, 2320\u20132324 (2023).","journal-title":"Rheumatology"},{"key":"1033_CR165","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1136\/annrheumdis-2017-212149","volume":"77","author":"Y Kochi","year":"2018","unstructured":"Kochi, Y. et al. Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Ann. Rheum. Dis. 77, 602\u2013611 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1033_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34116-9","volume":"13","author":"SH Chan","year":"2022","unstructured":"Chan, S. H. et al. Analysis of clinically relevant variants from ancestrally diverse Asian genomes. Nat. Commun. 13, 6694 (2022).","journal-title":"Nat. Commun."},{"key":"1033_CR167","doi-asserted-by":"publisher","first-page":"151932","DOI":"10.1016\/j.semarthrit.2021.12.004","volume":"52","author":"MH Lee","year":"2022","unstructured":"Lee, M. H. et al. A meta-analysis of clinical manifestations in Asian systemic lupus erythematous: the effects of ancestry, ethnicity and gender. Semin. Arthritis Rheum. 52, 151932 (2022).","journal-title":"Semin. Arthritis Rheum."},{"key":"1033_CR168","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/23971983221074749","volume":"7","author":"SA Ng","year":"2022","unstructured":"Ng, S. A. & Low, A. H. L. Systemic sclerosis in Asians: are there racial differences? J. Scleroderma Relat. Disord. 7, 98\u2013109 (2022).","journal-title":"J. Scleroderma Relat. Disord."},{"key":"1033_CR169","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1128\/CMR.00001-08","volume":"21","author":"NF Crum-Cianflone","year":"2008","unstructured":"Crum-Cianflone, N. F. Bacterial, fungal, parasitic, and viral myositis. Clin. Microbiol. Rev. 21, 473\u2013494 (2008).","journal-title":"Clin. Microbiol. Rev."},{"key":"1033_CR170","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12969-021-00570-w","volume":"19","author":"N Movahedi","year":"2021","unstructured":"Movahedi, N. & Ziaee, V. COVID-19 and myositis; true dermatomyositis or prolonged post viral myositis? Pediatr. Rheumatol. Online J. 19, 86 (2021).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"1033_CR171","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11926-021-01023-9","volume":"23","author":"A Saud","year":"2021","unstructured":"Saud, A., Naveen, R., Aggarwal, R. & Gupta, L. COVID-19 and myositis: what we know so far. Curr. Rheumatol. Rep. 23, 63 (2021).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1033_CR172","first-page":"316","volume":"41","author":"F Kharouf","year":"2023","unstructured":"Kharouf, F. et al. Increased rates of idiopathic inflammatory myopathies during the COVID-19 pandemic: a single-centre experience. Clin. Exp. Rheumatol. 41, 316\u2013321 (2023).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1033_CR173","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","volume":"95","author":"Y Allenbach","year":"2020","unstructured":"Allenbach, Y. et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases. Neurology 95, e70\u2013e78 (2020).","journal-title":"Neurology"},{"key":"1033_CR174","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00296-021-04819-1","volume":"41","author":"P Mehta","year":"2021","unstructured":"Mehta, P., Machado, P. M. & Gupta, L. Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol. Int. 41, 1021\u20131036 (2021).","journal-title":"Rheumatol. Int."},{"key":"1033_CR175","doi-asserted-by":"publisher","first-page":"791348","DOI":"10.3389\/fimmu.2021.791348","volume":"12","author":"G Wang","year":"2021","unstructured":"Wang, G. et al. Presence of anti-MDA5 antibody and its value for the clinical assessment in patients with COVID-19: a retrospective cohort study. Front. Immunol. 12, 791348 (2021).","journal-title":"Front. Immunol."},{"key":"1033_CR176","doi-asserted-by":"publisher","first-page":"1007637","DOI":"10.3389\/fpubh.2022.1007637","volume":"10","author":"Y Ding","year":"2022","unstructured":"Ding, Y. & Ge, Y. Inflammatory myopathy following coronavirus disease 2019 vaccination: a systematic review. Front. Public. Health 10, 1007637 (2022).","journal-title":"Front. Public. Health"},{"key":"1033_CR177","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00296-016-3555-7","volume":"36","author":"J Roszkiewicz","year":"2016","unstructured":"Roszkiewicz, J. & Smolewska, E. Kaleidoscope of autoimmune diseases in HIV infection. Rheumatol. Int. 36, 1481\u20131491 (2016).","journal-title":"Rheumatol. Int."},{"key":"1033_CR178","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1212\/WNL.0000000000003821","volume":"88","author":"TE Lloyd","year":"2017","unstructured":"Lloyd, T. E. et al. Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. Neurology 88, 1454\u20131460 (2017).","journal-title":"Neurology"},{"key":"1033_CR179","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/jnnp-2018-319419","volume":"90","author":"O Landon-Cardinal","year":"2019","unstructured":"Landon-Cardinal, O. et al. Expanding the spectrum of HIV-associated myopathy. J. Neurol. Neurosurg. Psychiatry 90, 1296\u20131298 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1033_CR180","first-page":"86","volume":"18","author":"T Nojima","year":"2000","unstructured":"Nojima, T. et al. A case of polymyositis associated with hepatitis B infection. Clin. Exp. Rheumatol. 18, 86\u201388 (2000).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1033_CR181","first-page":"S261","volume":"1","author":"JC Milisenda","year":"2014","unstructured":"Milisenda, J. C. et al. Polymyositis-associated to chronic hepatitis C virus infection. J. Neuromuscul. Dis. 1, S261\u2013S262 (2014).","journal-title":"J. Neuromuscul. Dis."},{"key":"1033_CR182","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1212\/WNL.0000000000002291","volume":"86","author":"A Uruha","year":"2016","unstructured":"Uruha, A. et al. Hepatitis C virus infection in inclusion body myositis: a case-control study. Neurology 86, 211\u2013217 (2016).","journal-title":"Neurology"},{"key":"1033_CR183","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.amjms.2020.05.011","volume":"360","author":"R Peravali","year":"2020","unstructured":"Peravali, R., Acharya, S., Raza, S. H., Pattanaik, D. & Randall, M. B. Dermatomyositis developed after exposure to Epstein-Barr virus infection and antibiotics use. Am. J. Med. Sci. 360, 402\u2013405 (2020).","journal-title":"Am. J. Med. Sci."},{"key":"1033_CR184","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05506-5","volume":"20","author":"V Sakthivadivel","year":"2020","unstructured":"Sakthivadivel, V. et al. Concurrent acute myositis and Guillain-Barre syndrome in Cytomegalovirus infection \u2014 a rare case report. BMC Infect. Dis. 20, 768 (2020).","journal-title":"BMC Infect. Dis."},{"key":"1033_CR185","first-page":"250537","volume":"2012","author":"ND Oliver","year":"2012","unstructured":"Oliver, N. D., Millar, A. & Pendleton, A. A case report on parvovirus B19 associated myositis. Case Rep. Rheumatol. 2012, 250537 (2012).","journal-title":"Case Rep. Rheumatol."},{"key":"1033_CR186","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s42003-021-01932-6","volume":"4","author":"S Megremis","year":"2021","unstructured":"Megremis, S. et al. Analysis of human total antibody repertoires in TIF1\u03b3 autoantibody positive dermatomyositis. Commun. Biol. 4, 419 (2021).","journal-title":"Commun. Biol."},{"key":"1033_CR187","doi-asserted-by":"crossref","unstructured":"Top 10 drugs 2019\u201320. Aust. Prescr. 43, 209 (2020).","DOI":"10.18773\/austprescr.2020.075"},{"key":"1033_CR188","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1111\/bcp.13709","volume":"84","author":"S Audi","year":"2018","unstructured":"Audi, S. et al. The \u2018top 100\u2019 drugs and classes in England: an updated \u2018starter formulary\u2019 for trainee prescribers. Br. J. Clin. Pharmacol. 84, 2562\u20132571 (2018).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1033_CR189","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/pharmacy6020043","volume":"6","author":"AV Fuentes","year":"2018","unstructured":"Fuentes, A. V., Pineda, M. D. & Venkata, K. C. N. Comprehension of top 200 prescribed drugs in the us as a resource for pharmacy teaching, training and practice. Pharmacy 6, 43 (2018).","journal-title":"Pharmacy"},{"key":"1033_CR190","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41569-018-0098-5","volume":"15","author":"BB Adhyaru","year":"2018","unstructured":"Adhyaru, B. B. & Jacobson, T. A. Safety and efficacy of statin therapy. Nat. Rev. Cardiol. 15, 757\u2013769 (2018).","journal-title":"Nat. Rev. Cardiol."},{"key":"1033_CR191","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/clpt.2014.121","volume":"96","author":"A Alfirevic","year":"2014","unstructured":"Alfirevic, A. et al. Phenotype standardization for statin-induced myotoxicity. Clin. Pharmacol. Ther. 96, 470\u2013476 (2014).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1033_CR192","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11926-018-0763-z","volume":"20","author":"L Ladislau","year":"2018","unstructured":"Ladislau, L., Arouche-Delaperche, L., Allenbach, Y. & Benveniste, O. Potential pathogenic role of anti-signal recognition protein and anti-3-hydroxy-3-methylglutaryl-CoA reductase antibodies in immune-mediated necrotizing myopathies. Curr. Rheumatol. Rep. 20, 56 (2018).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1033_CR193","doi-asserted-by":"publisher","first-page":"103304","DOI":"10.1016\/j.amsu.2022.103304","volume":"74","author":"W Abed","year":"2022","unstructured":"Abed, W., Abujbara, M., Batieha, A. & Ajlouni, K. Statin induced myopathy among patients attending the National Center for Diabetes, Endocrinology, & Genetics. Ann. Med. Surg. 74, 103304 (2022).","journal-title":"Ann. Med. Surg."},{"key":"1033_CR194","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","volume":"106","author":"RC Pasternak","year":"2002","unstructured":"Pasternak, R. C. et al. ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins. Circulation 106, 1024\u20131028 (2002).","journal-title":"Circulation"},{"key":"1033_CR195","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/aoms.2015.49807","volume":"11","author":"M Banach","year":"2015","unstructured":"Banach, M. et al. Statin intolerance \u2014 an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch. Med. Sci. 11, 1\u201323 (2015).","journal-title":"Arch. Med. Sci."},{"key":"1033_CR196","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1007\/s11606-021-06651-6","volume":"36","author":"AM Mueller","year":"2021","unstructured":"Mueller, A. M. et al. The risk of muscular events among new users of hydrophilic and lipophilic statins: an observational cohort study. J. Gen. Intern. Med. 36, 2639\u20132647 (2021).","journal-title":"J. Gen. Intern. Med."},{"key":"1033_CR197","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","volume":"400","author":"Cholesterol Treatment Trialists\u2019 Collaboration.","year":"2022","unstructured":"Cholesterol Treatment Trialists\u2019 Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet 400, 832\u2013845 (2022).","journal-title":"Lancet"},{"key":"1033_CR198","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jclinepi.2006.11.006","volume":"60","author":"DL McClure","year":"2007","unstructured":"McClure, D. L., Valuck, R. J., Glanz, M., Murphy, J. R. & Hokanson, J. E. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. J. Clin. Epidemiol. 60, 812\u2013818 (2007).","journal-title":"J. Clin. Epidemiol."},{"key":"1033_CR199","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.cjca.2016.01.003","volume":"32","author":"GB Mancini","year":"2016","unstructured":"Mancini, G. B. et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian consensus working group update (2016). Can. J. Cardiol. 32, S35\u201365 (2016).","journal-title":"Can. J. Cardiol."},{"key":"1033_CR200","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16, 223\u2013249 (2021).","journal-title":"Annu. Rev. Pathol."},{"key":"1033_CR201","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals, M. et al. Immune-related adverse events of checkpoint inhibitors. Nat. Rev. Dis. Prim. 6, 38 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1033_CR202","doi-asserted-by":"publisher","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","volume":"13","author":"A Chennamadhavuni","year":"2022","unstructured":"Chennamadhavuni, A., Abushahin, L., Jin, N., Presley, C. J. & Manne, A. Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front. Immunol. 13, 779691 (2022).","journal-title":"Front. Immunol."},{"key":"1033_CR203","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","volume":"14","author":"LH Calabrese","year":"2018","unstructured":"Calabrese, L. H., Calabrese, C. & Cappelli, L. C. Rheumatic immune-related adverse events from cancer immunotherapy. Nat. Rev. Rheumatol. 14, 569\u2013579 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1033_CR204","doi-asserted-by":"publisher","first-page":"803410","DOI":"10.3389\/fimmu.2021.803410","volume":"12","author":"N Hamada","year":"2021","unstructured":"Hamada, N. et al. Incidence and distinct features of immune checkpoint inhibitor-related myositis from idiopathic inflammatory myositis: a single-center experience with systematic literature review and meta-analysis. Front. Immunol. 12, 803410 (2021).","journal-title":"Front. Immunol."},{"key":"1033_CR205","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/RHU.0000000000001874","volume":"28","author":"D Saygin","year":"2022","unstructured":"Saygin, D., Ghosh, N. & Reid, P. Immune checkpoint inhibitor-associated myositis: a distinct form of inflammatory myopathy. J. Clin. Rheumatol. 28, 367\u2013373 (2022).","journal-title":"J. Clin. Rheumatol."},{"key":"1033_CR206","doi-asserted-by":"publisher","first-page":"fcaa181","DOI":"10.1093\/braincomms\/fcaa181","volume":"2","author":"S Shelly","year":"2020","unstructured":"Shelly, S. et al. Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain Commun. 2, fcaa181 (2020).","journal-title":"Brain Commun."},{"key":"1033_CR207","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/cam4.5050","volume":"12","author":"J Longinow","year":"2023","unstructured":"Longinow, J. et al. Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: a single-center case series. Cancer Med. 12, 2281\u20132289 (2023).","journal-title":"Cancer Med."},{"key":"1033_CR208","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","volume":"357","author":"CL Hill","year":"2001","unstructured":"Hill, C. L. et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357, 96\u2013100 (2001).","journal-title":"Lancet"},{"key":"1033_CR209","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","volume":"77","author":"JB Lilleker","year":"2018","unstructured":"Lilleker, J. B. et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann. Rheum. Dis. 77, 30\u201339 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1033_CR210","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1007\/s10067-019-04782-0","volume":"39","author":"YK Sung","year":"2020","unstructured":"Sung, Y. K. et al. Temporal relationship between idiopathic inflammatory myopathies and malignancies and its mortality: a nationwide population-based study. Clin. Rheumatol. 39, 3409\u20133416 (2020).","journal-title":"Clin. Rheumatol."},{"key":"1033_CR211","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.semarthrit.2020.12.009","volume":"51","author":"L Dani","year":"2021","unstructured":"Dani, L., Ian Che, W., Lundberg, I. E., Hellgren, K. & Holmqvist, M. Overall and site-specific cancer before and after diagnosis of idiopathic inflammatory myopathies: a nationwide study 2002\u20132016. Semin. Arthritis Rheum. 51, 331\u2013337 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"1033_CR212","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jns.2017.03.033","volume":"377","author":"JP Stubgen","year":"2017","unstructured":"Stubgen, J. P. Juvenile dermatomyositis\/polymyositis and lymphoma. J. Neurol. Sci. 377, 19\u201324 (2017).","journal-title":"J. Neurol. Sci."},{"key":"1033_CR213","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","volume":"87","author":"A Hida","year":"2016","unstructured":"Hida, A. et al. Anti-TIF1-\u03b3 antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology 87, 299\u2013308 (2016).","journal-title":"Neurology"},{"key":"1033_CR214","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/key357","volume":"58","author":"A Oldroyd","year":"2019","unstructured":"Oldroyd, A. et al. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. Rheumatology 58, 650\u2013655 (2019).","journal-title":"Rheumatology"},{"key":"1033_CR215","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/rheumatology\/kez572","volume":"59","author":"J De Vooght","year":"2020","unstructured":"De Vooght, J. et al. Anti-TIF1-\u03b3 autoantibodies: warning lights of a tumour autoantigen. Rheumatology 59, 469\u2013477 (2020).","journal-title":"Rheumatology"},{"key":"1033_CR216","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/art.42474","volume":"75","author":"D Fiorentino","year":"2023","unstructured":"Fiorentino, D. et al. Anti-CCAR1 autoantibodies are specific for anti-TIF1\u03b3-positive dermatomyositis and decrease cancer risk relative to the general population. Arthritis Rheumatol. 75, 1238\u20131245 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1033_CR217","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/ard-2022-222441","volume":"82","author":"Y Hosono","year":"2023","unstructured":"Hosono, Y. et al. Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1\u03b3 autoantibodies. Ann. Rheum. Dis. 82, 246\u2013252 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1033_CR218","doi-asserted-by":"crossref","unstructured":"Sherman, M. A. et al. Anti-Sp4 autoantibodies co-occur with anti-TIF1 and are associated with distinct clinical features and immunogenetic risk factors in juvenile myositis. Arthritis Rheumatol. 75, 1668\u20131677(2023).","DOI":"10.1002\/art.42512"},{"key":"1033_CR219","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00296-012-2489-y","volume":"33","author":"V Limaye","year":"2013","unstructured":"Limaye, V. et al. The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol. Int. 33, 965\u2013971 (2013).","journal-title":"Rheumatol. Int."},{"key":"1033_CR220","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1136\/annrheumdis-2015-eular.3401","volume":"74","author":"SJ Lee","year":"2015","unstructured":"Lee, S. J. et al. Cancer risks in Korean patients with myositis: comparison between cancers related and unrelated to myositis activity. Ann. Rheum. Dis. 74, 832 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1033_CR221","first-page":"5960","volume":"16","author":"Y Liu","year":"2018","unstructured":"Liu, Y. et al. Characteristics and predictors of malignancy in dermatomyositis: analysis of 239 patients from northern China. Oncol. Lett. 16, 5960\u20135968 (2018).","journal-title":"Oncol. Lett."},{"key":"1033_CR222","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1002\/art.11090","volume":"48","author":"S Okada","year":"2003","unstructured":"Okada, S. et al. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum. 48, 2285\u20132293 (2003).","journal-title":"Arthritis Rheum."},{"key":"1033_CR223","doi-asserted-by":"publisher","first-page":"842586","DOI":"10.3389\/fmed.2022.842586","volume":"9","author":"MM Hossain","year":"2022","unstructured":"Hossain, M. M. et al. The geospatial distribution of myositis and its phenotypes in the united states and associations with roadways: findings from a national myositis patient registry. Front. Med. 9, 842586 (2022).","journal-title":"Front. Med."},{"key":"1033_CR224","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001202","volume":"6","author":"N Nishina","year":"2020","unstructured":"Nishina, N., Sato, S., Masui, K., Gono, T. & Kuwana, M. Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease. RMD Open. 6, e001202 (2020).","journal-title":"RMD Open."},{"key":"1033_CR225","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1136\/annrheumdis-2020-eular.5882","volume":"79","author":"H So","year":"2020","unstructured":"So, H. et al. Seasonal variation in idiopathic inflammatory myopathies incidence and presentation: a retrospective study in Beijing and Hong Kong. Ann. Rheum. Dis. 79, 1601\u20131602 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1033_CR226","doi-asserted-by":"publisher","first-page":"102788","DOI":"10.1016\/j.autrev.2021.102788","volume":"20","author":"S Toquet","year":"2021","unstructured":"Toquet, S. et al. The seasonality of dermatomyositis associated with anti-MDA5 antibody: an argument for a respiratory viral trigger. Autoimmun. Rev. 20, 102788 (2021).","journal-title":"Autoimmun. Rev."},{"key":"1033_CR227","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/acr.23188","volume":"69","author":"J Albayda","year":"2017","unstructured":"Albayda, J. et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res. 69, 1771\u20131776 (2017).","journal-title":"Arthritis Care Res."},{"key":"1033_CR228","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41584-019-0186-x","volume":"15","author":"SA Greenberg","year":"2019","unstructured":"Greenberg, S. A. Inclusion body myositis: clinical features and pathogenesis. Nat. Rev. Rheumatol. 15, 257\u2013272 (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1033_CR229","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12016-015-8513-8","volume":"52","author":"H Gunawardena","year":"2017","unstructured":"Gunawardena, H. The clinical features of myositis-associated autoantibodies: a review. Clin. Rev. Allergy Immunol. 52, 45\u201357 (2017).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"1033_CR230","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrrheum.2018.41","volume":"14","author":"IE Lundberg","year":"2018","unstructured":"Lundberg, I. E., de Visser, M. & Werth, V. P. Classification of myositis. Nat. Rev. Rheumatol. 14, 269\u2013278 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1033_CR231","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3899\/jrheum.221067","volume":"50","author":"NJ McHugh","year":"2023","unstructured":"McHugh, N. J. Ro52, myositis, and interstitial lung disease. J. Rheumatol. 50, 161\u2013163 (2023).","journal-title":"J. Rheumatol."},{"key":"1033_CR232","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","volume":"52","author":"M Satoh","year":"2017","unstructured":"Satoh, M., Tanaka, S., Ceribelli, A., Calise, S. J. & Chan, E. K. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin. Rev. Allergy Immunol. 52, 1\u201319 (2017).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"1033_CR233","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3233\/JND-210669","volume":"8","author":"M Monaghan","year":"2021","unstructured":"Monaghan, M. et al. Inflammatory myositis secondary to anti-retroviral therapy in a child; case report and review of the literature. J. Neuromuscul. Dis. 8, 1089\u20131095 (2021).","journal-title":"J. Neuromuscul. Dis."},{"key":"1033_CR234","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1365-4632.2011.05105.x","volume":"51","author":"A Nofal","year":"2012","unstructured":"Nofal, A. & El-Din, E. S. Hydroxyurea-induced dermatomyositis: true amyopathic dermatomyositis or dermatomyositis-like eruption? Int. J. Dermatol. 51, 535\u2013541 (2012).","journal-title":"Int. J. Dermatol."},{"key":"1033_CR235","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1345\/aph.1M411","volume":"44","author":"M Hahn","year":"2010","unstructured":"Hahn, M., Sriharan, K. & McFarland, M. S. Gemfibrozil-induced myositis in a patient with normal renal function. Ann. Pharmacother. 44, 211\u2013214 (2010).","journal-title":"Ann. Pharmacother."},{"key":"1033_CR236","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.11622\/smedj.2013145","volume":"54","author":"AY Lim","year":"2013","unstructured":"Lim, A. Y., Kek, P. C. & Soh, A. W. Carbimazole-induced myositis in the treatment of Graves\u2019 disease: a complication in genetically susceptible individuals? Singap. Med. J. 54, e133\u2013136 (2013).","journal-title":"Singap. Med. J."},{"key":"1033_CR237","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s12026-023-09368-2","volume":"71","author":"V Syrmou","year":"2023","unstructured":"Syrmou, V. et al. COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report. Immunol. Res. 71, 537\u2013546 (2023).","journal-title":"Immunol. Res."},{"key":"1033_CR238","first-page":"836930","volume":"2012","author":"C Ferri","year":"2012","unstructured":"Ferri, C. et al. Polymyositis following pandemic influenza A (H1N1) and 2009\u201310 seasonal trivalent vaccines. Case Rep. Rheumatol. 2012, 836930 (2012).","journal-title":"Case Rep. Rheumatol."},{"key":"1033_CR239","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00296-007-0485-4","volume":"28","author":"A Altman","year":"2008","unstructured":"Altman, A., Szyper-Kravitz, M. & Shoenfeld, Y. HBV vaccine and dermatomyositis: is there an association? Rheumatol. Int. 28, 609\u2013612 (2008).","journal-title":"Rheumatol. Int."},{"key":"1033_CR240","volume":"13","author":"H Chanbour","year":"2021","unstructured":"Chanbour, H., Jiblawi, A., Aboudalle, A., Alalman, O. & Chahine Elsett, Z. Association of silicosis and dermatomyositis: case report and literature review. Cureus 13, e19875 (2021).","journal-title":"Cureus"},{"key":"1033_CR241","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1002\/art.20587","volume":"50","author":"T O\u2019Hanlon","year":"2004","unstructured":"O\u2019Hanlon, T. et al. Immunogenetic differences between Caucasian women with and those without silicone implants in whom myositis develops. Arthritis Rheum. 50, 3646\u20133650 (2004).","journal-title":"Arthritis Rheum."},{"key":"1033_CR242","first-page":"376","volume":"22","author":"A Selva-O\u2019Callaghan","year":"2004","unstructured":"Selva-O\u2019Callaghan, A. et al. Silicone gel filled breast implants and dermatomyositis. Clin. Exp. Rheumatol. 22, 376 (2004).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1033_CR243","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11926-021-00996-x","volume":"23","author":"S Limaye","year":"2021","unstructured":"Limaye, S. & Limaye, V. Clinical characteristics of myositis associated with graft-versus-host disease. Curr. Rheumatol. Rep. 23, 30 (2021).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1033_CR244","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.4049\/jimmunol.172.8.5041","volume":"172","author":"AM Reed","year":"2004","unstructured":"Reed, A. M., McNallan, K., Wettstein, P., Vehe, R. & Ober, C. Does HLA-dependent chimerism underlie the pathogenesis of juvenile dermatomyositis? J. Immunol. 172, 5041\u20135046 (2004).","journal-title":"J. Immunol."},{"key":"1033_CR245","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","volume":"1","author":"Y Allanore","year":"2015","unstructured":"Allanore, Y. et al. Systemic sclerosis. Nat. Rev. Dis. Prim. 1, 15002 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1033_CR246","doi-asserted-by":"publisher","first-page":"16047","DOI":"10.1038\/nrdp.2016.47","volume":"2","author":"P Brito-Zeron","year":"2016","unstructured":"Brito-Zeron, P. et al. Sjogren syndrome. Nat. Rev. Dis. Prim. 2, 16047 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1033_CR247","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001888","volume":"7","author":"SSR Crossfield","year":"2021","unstructured":"Crossfield, S. S. R., Marzo-Ortega, H., Kingsbury, S. R., Pujades-Rodriguez, M. & Conaghan, P. G. Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades. RMD Open. 7, e001888 (2021).","journal-title":"RMD Open."},{"key":"1033_CR248","first-page":"ii14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman, D. D., Antoni, C., Mease, P., Clegg, D. O. & Nash, P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis. 64, ii14\u201317 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"1033_CR249","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","volume":"18","author":"RA Watts","year":"2022","unstructured":"Watts, R. A., Hatemi, G., Burns, J. C. & Mohammad, A. J. Global epidemiology of vasculitis. Nat. Rev. Rheumatol. 18, 22\u201334 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1033_CR250","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","volume":"78","author":"S Safiri","year":"2019","unstructured":"Safiri, S. et al. Global, regional and national burden of rheumatoid arthritis 1990\u20132017: a systematic analysis of the Global Burden of Disease study 2017. Ann. Rheum. Dis. 78, 1463\u20131471 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1033_CR251","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1378\/chest.10-0180","volume":"138","author":"GR Connors","year":"2010","unstructured":"Connors, G. R., Christopher-Stine, L., Oddis, C. V. & Danoff, S. K. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 138, 1464\u20131474 (2010).","journal-title":"Chest"},{"key":"1033_CR252","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1590\/S1806-37132011000100015","volume":"37","author":"J Solomon","year":"2011","unstructured":"Solomon, J., Swigris, J. J. & Brown, K. K. Myositis-related interstitial lung disease and antisynthetase syndrome. J. Bras. Pneumol. 37, 100\u2013109 (2011).","journal-title":"J. Bras. Pneumol."},{"key":"1033_CR253","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejim.2022.04.017","volume":"101","author":"D Prieto-Pena","year":"2022","unstructured":"Prieto-Pena, D. et al. Epidemiological and genetic features of anti-3-hydroxy-3-methylglutaryl-CoA reductase necrotizing myopathy: single-center experience and literature review. Eur. J. Intern. Med. 101, 86\u201392 (2022).","journal-title":"Eur. J. Intern. Med."},{"key":"1033_CR254","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/mus.27504","volume":"65","author":"S Shelly","year":"2022","unstructured":"Shelly, S. et al. Incidence and prevalence of immune-mediated necrotizing myopathy in adults in Olmsted County, Minnesota. Muscle Nerve 65, 541\u2013546 (2022).","journal-title":"Muscle Nerve"},{"key":"1033_CR255","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3233\/JND-170282","volume":"5","author":"P Mohassel","year":"2018","unstructured":"Mohassel, P. & Mammen, A. L. Anti-HMGCR myopathy. J. Neuromuscul. Dis. 5, 11\u201320 (2018).","journal-title":"J. Neuromuscul. Dis."},{"key":"1033_CR256","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-248880","volume":"15","author":"B Adler","year":"2022","unstructured":"Adler, B., Christopher-Stine, L. & Tiniakou, E. Mushroom supplements triggering a flare of HMGCR immune mediated necrotising myopathy. BMJ Case Rep. 15, e248880 (2022).","journal-title":"BMJ Case Rep."},{"key":"1033_CR257","doi-asserted-by":"publisher","first-page":"474","DOI":"10.7326\/0003-4819-145-6-200609190-00021","volume":"145","author":"PS Mueller","year":"2006","unstructured":"Mueller, P. S. Symptomatic myopathy due to red yeast rice. Ann. Intern. Med. 145, 474\u2013475 (2006).","journal-title":"Ann. Intern. Med."},{"key":"1033_CR258","doi-asserted-by":"publisher","first-page":"8787","DOI":"10.1021\/jf071629p","volume":"55","author":"KC Jeng","year":"2007","unstructured":"Jeng, K. C., Chen, C. S., Fang, Y. P., Hou, R. C. & Chen, Y. S. Effect of microbial fermentation on content of statin, GABA, and polyphenols in Pu-Erh tea. J. Agric. Food Chem. 55, 8787\u20138792 (2007).","journal-title":"J. Agric. Food Chem."},{"key":"1033_CR259","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/mus.27758","volume":"67","author":"AM Yaworski","year":"2023","unstructured":"Yaworski, A. M., Blyumin, M., Chang, T., Mammen, A. L. & Greene, M. Necrotizing myopathy with elevated anti-HMGCR antibodies following exposure to the supplement Bacopa. Muscle Nerve 67, E1\u2013E3 (2023).","journal-title":"Muscle Nerve"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01033-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01033-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01033-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T08:28:11Z","timestamp":1711096091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01033-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":259,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1033"],"URL":"https:\/\/doi.org\/10.1038\/s41584-023-01033-0","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,6]]},"assertion":[{"value":"5 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}